Together, these findings suggest that CB2R could promote steatosis directly by inducing liver inflammation, contributing to NASH, and indirectly by increasing the hepatic CB1R expression, thereby contributing to NAFLD, NASH, and liver fibrosis. Here, CNR1 is linked to metabolic dysfunction-associated steatohepatitis.